PLCB1

PLCB1 encodes phospholipase C β1, a phosphoinositide-specific phospholipase C whose catalytic domain hydrolyzes phosphoinositides to generate second messengers, functioning at the intersection of G-protein–coupled receptor signaling, cytoskeletal remodeling, and oncogenic PI3K/AKT activation (PMID:2455601). PLCB1 activates PI3K/AKT/GSK3β/Snail signaling to drive epithelial-to-mesenchymal transition in cholangiocarcinoma and gastric cancer, with PABPC1 forming a ternary complex with PLCB1 and PI3K to amplify AKT output, and additionally remodels the actin cytoskeleton through the RhoA/LIMK/Cofilin pathway (PMID:34580062, PMID:37208557). PLCB1 also promotes ubiquitin-dependent proteasomal degradation of β-catenin independently of the canonical destruction complex, thereby suppressing Wnt signaling; loss of PLCB1 through miR-1290–mediated silencing leads to β-catenin accumulation and chemoresistance in glioma (PMID:39053384). In the nervous system, heterozygous deletion of Plcb1 in mice reduces cue-induced cocaine-seeking behavior and alters prefrontal cortex transcriptomic programs related to dopaminergic signaling and synaptic plasticity (PMID:34635637).

1. 1988 High

   The identity and enzymatic function of PLCβ1 were established: cloning and expression of PLC-154 demonstrated that the gene encodes a phosphoinositide-specific phospholipase C with a catalytic domain mapped to the central region of the protein, founding the PLCβ family.

   Evidence cDNA cloning and transient expression in COS-1 cells with functional phospholipase C activity readout

   PMID:2455601

   Open questions at the time

   • Regulation of PLCβ1 expression and upstream activating signals were unknown
   • Downstream effector pathways beyond inositol phosphate/DAG generation were not explored
   • No in vivo physiological role established
2. 2014 Medium

   A first transcriptional control mechanism was identified: EGR-1 binds the PLCB1 promoter and upregulates its expression >5-fold, connecting Gαq/11 signaling to PLCβ1 transcription in the context of cardiac hypertrophy.

   Evidence 5'-RACE promoter mapping, EMSA for EGR-1 binding, and luciferase reporter assays in human heart-derived system

   PMID:25192965

   Open questions at the time

   • No ChIP-seq or chromatin-level confirmation of EGR-1 occupancy in vivo
   • Other transcription factors controlling PLCB1 were not surveyed
   • Functional consequence of EGR-1-driven PLCβ1 increase in cardiac tissue not shown beyond promoter activity
3. 2021 Medium

   PLCβ1 was placed as a signaling hub in cancer: it activates PI3K/AKT/GSK3β/Snail to drive EMT in cholangiocarcinoma, with PABPC1 identified as a physical binding partner bridging PLCβ1 and PI3K, and miR-26b-5p shown to suppress PLCβ1 post-transcriptionally; separately, HDAC8 was found to upregulate PLCB1 to activate compensatory AKT signaling in MEK-inhibitor-resistant cells.

   Evidence Reciprocal Co-IP of PLCB1–PABPC1–PI3K complex, transposon-based in vivo tumor models with AKT inhibitor rescue, 3'UTR luciferase assays (miR-26b-5p); Affymetrix microarray and siRNA/HDAC-inhibitor epistasis for HDAC8–PLCB1–AKT axis

   PMID:34064422 PMID:34580062

   Open questions at the time

   • Whether PLCβ1's lipase activity is required for PI3K/AKT activation or whether it acts as a scaffold is unresolved
   • The structural basis of the PLCB1–PABPC1–PI3K ternary complex is unknown
   • HDAC8's mechanism for upregulating PLCB1 (direct deacetylation vs. indirect transcriptional effect) was not determined
4. 2021 Medium

   A neuronal function was established: heterozygous Plcb1 deletion in mice reduced cocaine-seeking behavior and altered prefrontal cortex gene expression in dopaminergic and synaptic plasticity pathways, demonstrating PLCβ1's role in reward circuitry.

   Evidence Plcb1+/− knockout mice tested in operant cocaine self-administration and cue-induced reinstatement paradigm with mPFC transcriptomics

   PMID:34635637

   Open questions at the time

   • Cell-type-specific contributions (excitatory vs. inhibitory neurons) in the mPFC were not resolved
   • Whether PLCβ1 enzymatic activity or protein–protein interactions mediate the behavioral phenotype is unknown
   • Homozygous knockout phenotype and broader behavioral characterization not reported in this study
5. 2023 Low

   PLCβ1 was linked to cytoskeletal remodeling: it activates the RhoA/LIMK/Cofilin pathway to drive actin rearrangement and promotes migration/invasion in gastric cancer, expanding its effector repertoire beyond AKT.

   Evidence PLCB1 knockdown/overexpression with Western blot readouts of RhoA, p-LIMK, p-Cofilin and EMT markers in gastric cancer cells

   PMID:37208557

   Open questions at the time

   • No epistasis experiments (e.g., RhoA inhibitor rescue) to confirm pathway ordering
   • The mechanism connecting PLCβ1 enzymatic products to RhoA activation was not elucidated
   • Single-lab finding without independent confirmation
6. 2024 Medium

   A novel non-canonical Wnt-suppressive function was uncovered: PLCβ1 promotes ubiquitin-dependent proteasomal degradation of β-catenin independently of the canonical destruction complex, and its silencing by miR-1290 under hyperoxia drives Wnt-mediated chemoresistance in glioma.

   Evidence Ubiquitination assays, β-catenin degradation kinetics, miR-1290/PLCB1 epistasis, and in vivo glioma model with WNT974 rescue

   PMID:39053384

   Open questions at the time

   • The E3 ubiquitin ligase recruited by PLCβ1 to β-catenin is unidentified
   • Whether PLCβ1 directly binds β-catenin or acts through intermediates is unknown
   • Generalizability of destruction-complex-independent mechanism beyond glioma cells is untested

• A central unresolved question is whether PLCβ1's diverse downstream effects (PI3K/AKT, RhoA/Cofilin, β-catenin degradation) require its phospholipase catalytic activity or reflect scaffolding/adaptor functions; no catalytically dead mutant has been tested across these pathways.
• No structure–function analysis using catalytic-dead PLCβ1 mutants in cancer or neuronal contexts
• No comprehensive interactome beyond PABPC1 and PI3K
• No structural model of PLCβ1 engagement with β-catenin or RhoA pathway components